Intangible Assets

ZJYL does not appear to possess identifiable proprietary IP, brand power, or regulated exclusivity that would let it sustain pricing power versus larger healthcare peers.

The absence of disclosed long-run margin or ROIC evidence, combined with TTM ROIC of 0.76%, suggests any intangible advantage is not translating into durable economic returns.

Compared with branded pharmaceutical, device, or platform peers that monetize patents, clinical data, or regulatory barriers, ZJYL’s intangible moat looks materially weaker and more replicable.

Switching Costs

The company’s low TTM ROCE of 1.27% implies customers are not locked in by meaningful switching frictions that would preserve margins over time.

A cash conversion cycle of 243.5 days indicates working-capital intensity rather than customer lock-in, which is the opposite of a strong switching-cost moat.

Relative to peers with embedded workflows, recurring contracts, or clinical dependence, ZJYL shows little evidence of retention economics that would make replacement costly.

Network Effects

No evidence indicates that ZJYL operates a platform, marketplace, or data network where each additional user increases value for other users.

Unlike peer businesses with ecosystem-driven adoption or referral loops, ZJYL’s economics do not show self-reinforcing demand or usage-based lock-in.

The available metrics point to a conventional operating model, so network effects do not appear to be a source of durable advantage.

Cost Advantage

TTM asset turnover of 0.35x suggests ZJYL is not extracting unusually high revenue from its asset base, which argues against a structural cost edge.

Low ROIC and ROCE indicate the company is not converting operations into superior unit economics versus more efficient peers.

Compared with scaled competitors that benefit from procurement, manufacturing, or distribution leverage, ZJYL does not show evidence of a persistent cost advantage.

Efficient Scale

The available data do not show that ZJYL serves a niche large enough to support efficient-scale protection, where one or two firms can satisfy demand at lower cost than entrants.

Low returns on capital suggest the market is not structured in a way that allows the company to earn excess profits from limited competition.

Relative to peers with concentrated local networks or regulated capacity constraints, ZJYL does not appear to benefit from a defensible scale-based barrier.

Overall Score

ZJYL’s moat appears weak versus peers because the available evidence shows low capital returns, weak operating efficiency, and no clear signs of proprietary assets, switching costs, network effects, cost leadership, or efficient-scale protection.